全文获取类型
收费全文 | 1383830篇 |
免费 | 118487篇 |
国内免费 | 6450篇 |
专业分类
耳鼻咽喉 | 17459篇 |
儿科学 | 44420篇 |
妇产科学 | 37894篇 |
基础医学 | 191296篇 |
口腔科学 | 38060篇 |
临床医学 | 125194篇 |
内科学 | 286736篇 |
皮肤病学 | 32673篇 |
神经病学 | 114886篇 |
特种医学 | 57643篇 |
外国民族医学 | 316篇 |
外科学 | 216734篇 |
综合类 | 31935篇 |
现状与发展 | 2篇 |
一般理论 | 491篇 |
预防医学 | 110702篇 |
眼科学 | 29055篇 |
药学 | 97480篇 |
5篇 | |
中国医学 | 2331篇 |
肿瘤学 | 73455篇 |
出版年
2018年 | 14465篇 |
2017年 | 11380篇 |
2016年 | 13673篇 |
2015年 | 15321篇 |
2014年 | 21250篇 |
2013年 | 31887篇 |
2012年 | 39059篇 |
2011年 | 41900篇 |
2010年 | 26418篇 |
2009年 | 25638篇 |
2008年 | 38957篇 |
2007年 | 41510篇 |
2006年 | 42616篇 |
2005年 | 41022篇 |
2004年 | 39275篇 |
2003年 | 38009篇 |
2002年 | 36052篇 |
2001年 | 67573篇 |
2000年 | 69353篇 |
1999年 | 57720篇 |
1998年 | 16639篇 |
1997年 | 14721篇 |
1996年 | 15657篇 |
1995年 | 16700篇 |
1994年 | 15494篇 |
1993年 | 14573篇 |
1992年 | 48109篇 |
1991年 | 46789篇 |
1990年 | 44940篇 |
1989年 | 42794篇 |
1988年 | 39562篇 |
1987年 | 38864篇 |
1986年 | 36585篇 |
1985年 | 35325篇 |
1984年 | 26847篇 |
1983年 | 22566篇 |
1982年 | 14170篇 |
1981年 | 12772篇 |
1980年 | 11977篇 |
1979年 | 24008篇 |
1978年 | 17309篇 |
1977年 | 14628篇 |
1976年 | 13377篇 |
1975年 | 14012篇 |
1974年 | 16398篇 |
1973年 | 15665篇 |
1972年 | 14461篇 |
1971年 | 13282篇 |
1970年 | 12065篇 |
1969年 | 11279篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
Dental caries continues to be a severe oral health problem despite a decrease in its prevalence over the past few decades. The contemporary philosophy of caries management has shifted from the traditional approach to a newer medical one, that frequently includes utilization of fluoridated and antimicrobial agents. Among these different agents, Silver Diamine Fluoride (SDF)1 has gained significant recognition. Dr Nishino and Dr Yamaga in Japan, pioneered its application to arrest caries. It is an alkaline, colourless solution composed of diamine-silver and fluoride ions having silver's antibacterial and fluoride's remineralising property. It has been used successfully to arrest and prevent caries in deciduous and permanent teeth, prevent recurrence of secondary caries and treat dentinal hypersensitivity. No adverse systemic effects due to SDF have been noted although black discolouration following its application has raised concerns. When used wisely it is an effective, sustainable and inexpensive option for children with high caries risk, for individuals who cannot endure conventional modalities of restorative treatment and those with special health-care needs. The current review is an insight into the clinical significance and application of SDF based on published literature. 相似文献
62.
63.
Amandeep R. Mahal Laura D. Cramer Elyn H. Wang Shiyi Wang Amy J. Davidoff Cary P. Gross James B. Yu 《Journal of Geriatric Oncology》2021,12(1):102-105
ObjectivesAlthough survival after a cancer diagnosis has improved considerably over the past 20 years, little is known about trends in health-related quality-of-life (HRQOL) for older prostate, breast, and lung cancer survivors.MethodsUsing a population-based registry with longitudinal patient reported outcomes (the National Cancer Institute Surveillance, Epidemiology and End Results database linked to Medicare Health Outcomes Survey), we analyzed Medicare Advantage patients diagnosed with cancer during 1998–2011, who completed surveys regarding HRQOL through 2013. ‘Early Era’ patients were treated during 1998–2003; ‘Late Era’ patients were treated during 2006–2011. After propensity score matching, post-diagnosis changes in health utility (HU), Physical Component Summary (PCS) and Mental Component Summary (MCS) scores were calculated and compared between the two eras.ResultWe identified 208 older patients with prostate, 276 with breast and 76 with lung cancer who were treated in the ‘Early Era’ and matched to equal numbers in the ‘Late Era’. Mean age of patients in early and late era was 72 and 73 years, respectively. The mean post-diagnosis decline in health utility for patients treated in the ‘Late Era’ was not significantly different from the ‘Early Era’ for any cancer (Prostate [early vs. late]: ?0.06 vs. -0.03, p = .09; Breast: ?0.03 vs. ?0.04, p = .65; Lung: ?0.07 vs. ?0.07, p = .95); nor for Physical Component Summary or Mental Component Summary scores.ConclusionOlder patients treated for prostate, breast or lung cancer in the later era reported similar outcomes of changes in HRQOL compared to earlier era patients. 相似文献
64.
65.
Mt D. Dbrssy Chockalingam Ramanathan Danesh Ashouri Vajari Yixin Tong Thomas Schlaepfer Volker A. Coenen 《The European journal of neuroscience》2021,53(1):89-113
Deep brain stimulation (DBS) in psychiatric illnesses has been clinically tested over the past 20 years. The clinical application of DBS to the superolateral branch of the medial forebrain bundle in treatment‐resistant depressed patients—one of several targets under investigation—has shown to be promising in a number of uncontrolled open label trials. However, there are remain numerous questions that need to be investigated to understand and optimize the clinical use of DBS in depression, including, for example, the relationship between the symptoms, the biological substrates/projections and the stimulation itself. In the context of precision and customized medicine, the current paper focuses on clinical and experimental research of medial forebrain bundle DBS in depression or in animal models of depression, demonstrating how clinical and scientific progress can work in tandem to test the therapeutic value and investigate the mechanisms of this experimental treatment. As one of the hypotheses is that depression engenders changes in the reward and motivational networks, the review looks at how stimulation of the medial forebrain bundle impacts the dopaminergic system. 相似文献
66.
Nicolas Mottet Roderick C.N. van den Bergh Erik Briers Thomas Van den Broeck Marcus G. Cumberbatch Maria De Santis Stefano Fanti Nicola Fossati Giorgio Gandaglia Silke Gillessen Nikos Grivas Jeremy Grummet Ann M. Henry Theodorus H. van der Kwast Thomas B. Lam Michael Lardas Matthew Liew Malcolm D. Mason Philip Cornford 《European urology》2021,79(2):243-262
ObjectiveTo present a summary of the 2020 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on screening, diagnosis, and local treatment of clinically localised prostate cancer (PCa).Evidence acquisitionThe panel performed a literature review of new data, covering the time frame between 2016 and 2020. The guidelines were updated and a strength rating for each recommendation was added based on a systematic review of the evidence.Evidence synthesisA risk-adapted strategy for identifying men who may develop PCa is advised, generally commencing at 50 yr of age and based on individualised life expectancy. Risk-adapted screening should be offered to men at increased risk from the age of 45 yr and to breast cancer susceptibility gene (BRCA) mutation carriers, who have been confirmed to be at risk of early and aggressive disease (mainly BRAC2), from around 40 yr of age. The use of multiparametric magnetic resonance imaging in order to avoid unnecessary biopsies is recommended. When a biopsy is performed, a combination of targeted and systematic biopsies must be offered. There is currently no place for the routine use of tissue-based biomarkers. Whilst prostate-specific membrane antigen positron emission tomography computed tomography is the most sensitive staging procedure, the lack of outcome benefit remains a major limitation. Active surveillance (AS) should always be discussed with low-risk patients, as well as with selected intermediate-risk patients with favourable International Society of Urological Pathology (ISUP) 2 lesions. Local therapies are addressed, as well as the AS journey and the management of persistent prostate-specific antigen after surgery. A strong recommendation to consider moderate hypofractionation in intermediate-risk patients is provided. Patients with cN1 PCa should be offered a local treatment combined with long-term hormonal treatment.ConclusionsThe evidence in the field of diagnosis, staging, and treatment of localised PCa is evolving rapidly. The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on PCa summarise the most recent findings and advice for their use in clinical practice. These PCa guidelines reflect the multidisciplinary nature of PCa management.Patient summaryUpdated prostate cancer guidelines are presented, addressing screening, diagnosis, and local treatment with curative intent. These guidelines rely on the available scientific evidence, and new insights will need to be considered and included on a regular basis. In some cases, the supporting evidence for new treatment options is not yet strong enough to provide a recommendation, which is why continuous updating is important. Patients must be fully informed of all relevant options and, together with their treating physicians, decide on the most optimal management for them. 相似文献
67.
68.
Hajrunisa Cubro Karl A. Nath Sonja Suvakov Oscar Garcia-Valencia Santosh Parashuram Wendy M. White Tracey L. Weissgerber Meryl C. Nath Natasa M. Milic Fernando Sontag Livius V. d’Uscio Yi Zhu James L. Kirkland Tamar Tchkonia Mariam P. Alexander Reade A. Quinton Zvonimir S. Katusic Joseph P. Grande Vesna D. Garovic 《Kidney international》2021,99(3):646-656
69.
Toshiro Hara Rony Chanoch-Myers Nathan D. Mathewson Chad Myskiw Lyla Atta Lillian Bussema Stephen W. Eichhorn Alissa C. Greenwald Gabriela S. Kinker Christopher Rodman L. Nicolas Gonzalez Castro Hiroaki Wakimoto Orit Rozenblatt-Rosen Xiaowei Zhuang Jean Fan Tony Hunter Inder M. Verma Kai W. Wucherpfennig Itay Tirosh 《Cancer cell》2021,39(6):779-792.e11
70.
E.D.H. Gates J.S. Weinberg S.S. Prabhu J.S. Lin J. Hamilton J.D. Hazle G.N. Fuller V. Baladandayuthapani D.T. Fuentes D. Schellingerhout 《AJNR. American journal of neuroradiology》2021,42(1):102
BACKGROUND AND PURPOSE:Increased cellular density is a hallmark of gliomas, both in the bulk of the tumor and in areas of tumor infiltration into surrounding brain. Altered cellular density causes altered imaging findings, but the degree to which cellular density can be quantitatively estimated from imaging is unknown. The purpose of this study was to discover the best MR imaging and processing techniques to make quantitative and spatially specific estimates of cellular density.MATERIALS AND METHODS:We collected stereotactic biopsies in a prospective imaging clinical trial targeting untreated patients with gliomas at our institution undergoing their first resection. The data included preoperative MR imaging with conventional anatomic, diffusion, perfusion, and permeability sequences and quantitative histopathology on biopsy samples. We then used multiple machine learning methodologies to estimate cellular density using local intensity information from the MR images and quantitative cellular density measurements at the biopsy coordinates as the criterion standard.RESULTS:The random forest methodology estimated cellular density with R2 = 0.59 between predicted and observed values using 4 input imaging sequences chosen from our full set of imaging data (T2, fractional anisotropy, CBF, and area under the curve from permeability imaging). Limiting input to conventional MR images (T1 pre- and postcontrast, T2, and FLAIR) yielded slightly degraded performance (R2 = 0.52). Outputs were also reported as graphic maps.CONCLUSIONS:Cellular density can be estimated with moderate-to-strong correlations using MR imaging inputs. The random forest machine learning model provided the best estimates. These spatially specific estimates of cellular density will likely be useful in guiding both diagnosis and treatment.Increased cellular density (CD) is a hallmark of cancer and a key feature in histologic glioma analysis.1 Mapping cellular density throughout a tumor would be a valuable tool to probe how tumors infiltrate and analyze the transition between diseased and healthy brain. However, measuring CD requires tissue, which entails additional risks and is expensive to obtain. There is no currently accepted clinical algorithm to translate imaging data into quantitative assessments of CD.There is great need for a method to estimate CD noninvasively in human patients with gliomas. In this article, we describe the development of such a method using MR imaging data inputs by correlating with multiple biopsy specimens acquired during a prospective human clinical trial. We obtained comprehensive MR imaging, including conventional, diffusion, perfusion, and permeability imaging sequences. We used machine learning approaches to correlate imaging findings with CD measurements from pathology, devised an algorithm to estimate CD from MR imaging inputs, and generated CD maps for the visual display of the predictions. We identified the most informative imaging data subset. This work has multiple applications in the diagnosis and treatment of patients with gliomas: For example, the method can be used to guide biopsy, resection, and surgery and delineate tumor borderzones both pre- and postoperatively.2 相似文献